Company profile
CG Oncology, Inc.
NASDAQ:CGONBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cretostimogene Grenadenorepvec | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06111235 | phase3 | active_not_recruiting | 2023-12-14 | 2026-11-01 | CG Oncology, Inc. | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
| NCT01438112 | phase2_3 | terminated | 2014-03-01 | 2016-06-01 | CG Oncology, Inc. | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer |
| NCT06567743 | phase2 | recruiting | 2024-09-16 | 2027-03-31 | CG Oncology, Inc. | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
| NCT02365818 | phase2 | completed | 2015-06-02 | 2018-08-01 | CG Oncology, Inc. | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure |
| NCT02143804 | phase2 | withdrawn | 2014-03-01 | 2015-03-01 | CG Oncology, Inc. | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer |
FDA applications (0)
No records yet.